메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Lumonus Announces Transformative Multi-Year Licensing Agreement with Smarter Radiation Oncology® to bring evidenced-based directives to U.S. cancer centers

NEW YORK and SYDNEY, Sept. 30, 2025 -- Lumonus, a healthcare technology company transforming cancer care with its AI-powered platform, today announced a multi-year agreement with Smarter Radiation Oncology® (SRO), a company incubated by Northwell Health. Together, the organizations will advance the delivery of high-quality, standardized radiation therapy by combining Lumonus AI with SRO's evidence-based treatment protocols. Developed at Northwell Health, the largest health system in New York State, SRO's model for radiation therapy has
- 김갑성 기자
- 2025-09-30 00:00
Pierre Fabre Laboratories Announces Global Partnership with Know Your Lemons Foundation for Breast Cancer Awareness Month

Innovative Campaign Focuses on Early Detection and Empowering Education Throughout October CASTRES, France, Sept. 29, 2025 -- Pierre Fabre Laboratories is proud to announce the launch of a worldwide initiative in collaboration with the Know Your Lemons Foundation timed to coincide with Breast Cancer Awareness Month this October. This strategic partnership embodies our unwavering commitment to breast cancer prevention and supports the global mission of early detection through accessible and innovative education. Founded in 2014 by Corrine Ellsworth Beaumont, the Know Your
- 김갑성 기자
- 2025-09-29 23:36
트라이넷엑스, 2025년 글로벌 헬스케어 소프트웨어 부문 상위 25대 기업에 선정

'헬스케어 테크놀로지 리포트'의 이번 선정으로 트라이넷엑스는 실제 데이터, AI, 임상 연구 혁신 분야에서 이룬 혁신 입증 케임브리지, 매사추세츠주, 2025년 9월 29일 -- 세계에서 가장 광범위한 연합형 실사용 데이터(real-world data)와 증거 네트워크를 구축한 기업 트라이넷엑스(TriNetX)가 '헬스케어 테크놀로지 리포트(The Healthcare Technology Report)'가 선정한 '2025년 헬스케어 소프트웨어 부문 상위 25대 기업(Top 25 Healthcare Software Companies of 2025)'에 이름을 올렸다. 회사의 빠른 성장, 혁신적인 소프트웨어 솔루션, 생명과학과 헬스케어 분야에 대한 획기적인 기여가 이 권위 있는 상 수상으로 이어졌다. 스티브 쿤드로트(Steve Kundrot) 트라이넷엑스 최고운영책임자(COO)는 "이번 수상으로 트라이넷엑스는 데이터, 지능화, 기술을 통해 의료 생태계 전반의 혁신을 주도할 목적으로 적극적으로 추진해온 비전을 인정받았다"며 "우리는 개인정보 보호 규정을 준수하는 전 세계 실사용 데
- 김갑성 기자
- 2025-09-29 22:58
InnoMax MedTech Chairman Jackson Shih: Bridging Technical Gaps with End-to-End Services for Medical Device Manufacturers

SHANGHAI, Sept. 29, 2025 -- From September 24 to 26, InnoMax Medical Technology Co., Ltd. (InnoMax MedTech) featured its portfolio of proprietary products at 2025 Medtec China, spanning medical imaging and respiratory care. Among them was the company's proprietary Portable Mesh Nebulizer, alongside a portable oxygen concentrator, AI-enabled sleep-assist device, injection pens, and blood glucose meters, drawing strong interest from healthcare and medtech professionals. "Our product portfolio spans several key healthcare segments—from in-vitro diagnostics and medical imaging to res
- 김갑성 기자
- 2025-09-29 22:19
TriNetX Named Among the Top 25 Healthcare Software Companies of 2025

Recognition by The Healthcare Technology Report underscores TriNetX's innovation in real-world data, artificial intelligence, and clinical research transformation. CAMBRIDGE, Mass., Sept. 29, 2025 -- TriNetX, the company behind the world's broadest federated network of real-world data (RWD) and evidence, has been named one of the Top 25 Healthcare Software Companies of 2025 by The Healthcare Technology Report. This prestigious recognition celebrates TriNetX's rapid growth, pioneering software solutions, and transformative contributions to life sciences and healthcare. &
- 김갑성 기자
- 2025-09-29 20:49
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences

HHP and Hanmi will grant Gilead exclusive license to encequidar, and provide access to drug supply HONG KONG, Sept. 29, 2025 -- Health Hope Pharma Limited ("HHP") today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gilead") for encequidar, a first-in-class P-glycoprotein ("P-gp") inhibitor in the field of virology. HHP is currently exploring the potential of using encequidar to develop oral drug formulations across multiple fields. The most advanced program o
- 김갑성 기자
- 2025-09-29 20:48
Smartee Chief Scientist Prof. Gang Shen Recognized Among World's Top 2% Scientists for Orthodontic Contributions

SHANGHAI, Sept. 29, 2025 -- Smartee Denti-Technology today announced that Professor Gang Shen, its Chief Scientist and Executive President of TaiKang ByBo Dental, has once again been named to the World's Top 2% Scientists list, compiled by Stanford University in partnership with Elsevier. This marks the third consecutive year Prof. Shen has earned this prestigious recognition. Notably, he was honored in both the Career-Long Impact and Single-Year Impact categories, highlighting his long-term global impact and pioneering contributions to orthodontics. Now in its eighth edition,
- 김갑성 기자
- 2025-09-29 17:56
Hanmi's Oral Delivery Platform Compound Licensed to Gilead

Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply. SEOUL, South Korea, Sept. 29, 2025 -- Hanmi Pharm announced on September 29 that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gilead") and Health Hope Pharma ("HHP") granting Gilead the exclusive rights to develop and commercialize encequidar. Orascovery™ is an innovative oral drug delivery proprietary platform owned by Hanmi that enables the conversion of injectable medicines into oral
- 김갑성 기자
- 2025-09-29 17:45
Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry

Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical R&D ecosystem. SHANGHAI, Sept. 29, 2025 -- Viva Biotech announced today that it has been honored with Frost & Sullivan's 2025 APAC Technology Innovation Leadership recognition in the Integrated Intelligent Drug Discovery industry. As Frost & Sullivan's top honor, the award recognizes outstanding achievements in driving transformative efficiencies in preclinical research and developm
- 김갑성 기자
- 2025-09-29 17:00
루팡, GHO 캐피탈로부터 비쥬파마 인수...글로벌 전문 안과 사업 강화

런던, 로마, 스위스 추크, 2025년 9월 29일 -- 글로벌 메이저 제약회사 루팡(Lupin Limited)((BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN))이 29일 지분 100%를 보유한 자회사 나노미(Nanomi B.V.)를 통해 글로벌 헬스케어 전문 투자사 GHO 캐피털 파트너스(GHO Capital Partners LLP)로부터 비쥬파마(VISUfarma B.V.)를 인수하는 계약을 체결했다고 발표했다. 루팡은 유럽 사업과 입지를 확대하고 글로벌 전문 프랜차이즈를 발전시킨다는 전략에 따라 혁신적인 안과 건강 제품을 다양하게 보유하고 있고 판로도 확실한 비쥬파마를 인수했다. 루팡은 비쥬파마의 기존 영업망을 흡수해 전 세계 인구 고령화, 당뇨병 관련 안과 합병증 발생률 상승, 예방 치료에 대한 인식 증가에 따라 전 세계적으로 크게 성장하고 있는 안과 시장을 공략할 계획이다. 루팡은 비쥬파마의 유럽 영업망을 이용하면 이탈리아, 영국, 스페인, 독일, 프랑스 등 주요 유럽 국가에서 시장을 확대하고 입지를 강화하는 한편 사업도 다각화할 수 있을
- 김갑성 기자
- 2025-09-29 16:04

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-10-19_SUN

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 19일 03시 20분